Table 2 Summary of study results on the association between SGLT2 inhibitors (SGLT2i) and ventricular arrhythmias
From: SGLT2 inhibitors and the cardiac rhythm: unraveling the connections
Study name | SGLT2i | Year | Number of patients | Inclusion criteria | Findings |
|---|---|---|---|---|---|
Li et al. [61] | Multiple (Meta Analysis) | 2021 | 52,115 | RCTs that assigned patients with T2DM, CKD, or HF to either SGLT2is or a placebo | SGLT2i were associated with a 27% risk reduction in VT compared to placebo with highest reduction found for Canagliflozin |
Curtain et al. [10] | Dapagliflozin (DAPA-HF trial) | 2021 | 4744 | Adults with HF at NYHA functional class II–IV, an LVEF of ≤ 40%, raised NT-proBNP levels and were managed with both drug and device treatments for HFrEF | Patients on Dapagliflozin had reduced risk of VT, Cardiac Arrest or SCD compared to the control group |
Fernandes et al. [67] | Multiple (Meta Analysis) | 2021 | 63,166 | Randomized and double-blind design; SGLT2i and presence of a control group with diagnosed T2DM, HF, or both; and mandated follow-up of 24Â weeks | Treatment with SGLT2is was linked to a significant decrease in the SCD outcome when contrasted with the control |
Oates et al. [74] | Multiple (Meta Analysis) | 2023 | 10,796 SGLT2is and 10,796 controls | Patients with HF on SGLT2is and placebo | The use of SGLT2i therapy significantly reduced the likelihood of SCD |
von Lewinski et al. [79] | Ertugliflozin | 2022 | 402 | Patients with either reduced or mid-level EF, who had undergone ICD ± CRT treatment for over 3 months and had a history of VT were randomized in a 1:1 manner to either ertugliflozin or its corresponding placebo | This will be the inaugural trial evaluating ertugliflozin in HFrEF patients undergoing ICD ± CRT treatment, irrespective of their diabetes condition |